.Pharmacolibrary.Drugs.C_CardiovascularSystem.C01C_CardiacStimulantsExclCardiacGlycosides.C01CX08_Levosimendan.Levosimendan .Pharmacolibrary.Drugs.C_CardiovascularSystem.C01C_CardiacStimulantsExclCardiacGlycosides.C01CX08_Levosimendan.Levosimendan| name: | Levosimendan |
| ATC code: | C01CX08 | route: | intravenous |
| n-compartments | 2 |
Levosimendan is a calcium sensitizer and potassium channel opener used for short-term treatment of acute decompensated severe chronic heart failure in adults. It enhances myocardial contractility without increasing myocardial oxygen demand. It is approved in various countries but not in the United States.
Population pharmacokinetics in adult patients with severe heart failure following intravenous administration.
Jonsson, EN, et al., & Karlsson, MO (2003). Population pharmacokinetics of levosimendan in patients with congestive heart failure. British journal of clinical pharmacology 55(6) 544–551. DOI:10.1046/j.1365-2125.2003.01778.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12814448
Antila, S, et al., & Lehtonen, LA (2007). Clinical pharmacology of levosimendan. Clinical pharmacokinetics 46(7) 535–552. DOI:10.2165/00003088-200746070-00001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17596101
McBride, BF, & White, CM (2003). Levosimendan: implications for clinicians. Journal of clinical pharmacology 43(10) 1071–1081. DOI:10.1177/0091270003257217 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14517189